About Mitralign

Mitralign Inc.MITRALIGN, INC.

Mitralign, Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. We are a venture-backed, medical innovation company located near Boston, Massachusetts, USA.

We’ve developed an innovative therapy for the reduction of functional mitral regurgitation (FMR), a life-threatening cardiac condition affecting four million people in the U.S. alone1. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation (MR ≥ 3+) for annular reduction through tissue plication. In addition, we have developed an approach to treating tricuspid valve regurgitation with a delivery system designed for transcatheter tricuspid valve repair. Our unique system provides a new solution for interventional cardiologists and their patients.

For the millions of patients who’ve exhausted other therapeutic options, Mitralign is a lifeline.

  1. Jamieson WR, Edwards FH, Schwartz M, et al. Risk Stratification for Cardiac Valve Replacement. National Cardiac Surgery Database. Database Committee of the Society of Thoracic Surgeons. Ann Thorac Surg 1999;67:943-951

Management team

Board of Directors

Back to top

Mr. Geoffrion currently serves as the President and Chief Executive Officer of Mitralign, a venture-backed private company that has developed a transcatheter platform for mitral and tricuspid valve repair. Rick has over 30 years of management experience in the medical device industry and more than 25 years in the cardiovascular device space. A co-founder of Mitralign, he previously led the company foundation and served as the early stage CEO for three additional medical device companies (CircuLite, FlowMedica, X-Cell). He also guided the recapitalization and redirection of two successful medical device companies (Impella, Pathway). Mr. Geoffrion served as the Chairman of Impella CardioSystems AG, CircuLite and FlowMedica, Inc. He holds a BSME and an MBA from the University of Connecticut.

Lisa Wipperman Heine brings 25 years of medical device experience to Mitralign. Prior to joining Mitralign, Lisa was most recently Founder and Principal at deArca Strategic Solutions, LLC, a provider of medical device strategic consulting. Prior to deArca, Lisa was Global Vice President of Medical Affairs at Covidien in the Vascular Therapies Business Unit where she was responsible for the strategy and operations of Clinical Affairs, Healthcare Economics, Policy and Reimbursement and Professionals Affairs and Clinical Education (PACE). Her additional experience includes operational roles in regulatory affairs as well as sales and marketing. Lisa is also adjunct faculty in the Applied Clinical Research Graduate Program at St. Cloud State University. She received her bachelor’s degree from St. Olaf College and her graduate degree from the University of Manitoba.

Dr. Groothuis brings a wealth of experience to Mitralign. Prior to joining Mitralign, he was the VP and COO at CBSET, where he was responsible for research in cardiovascular devices. Previously, he was Assoc. Director of the Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He was also a Research Associate in the Harvard-MIT. Division of Health Sciences and Technology. Dr. Groothuis has authored numerous journal articles in the area of cardiovascular diseases. He received his BS from the University of California, Irvine, MS from Georgetown University, MBA from Salem State University and his PhD from Southern New Hampshire University.

Mr. Schleifer has over 20 years experience in the medical device, biotech and pharmaceutical industry. Prior to joining Mitralign, he held several key positions in management for Boston Scientific Corporation. During his eight-year tenure at BSC, he was responsible for business planning, product positioning and messaging, integrated channel management, competitive strategies and KOL management. Mr. Schleifer also has experience managing and monitoring Phase II-IV clinical trials for major pharmaceutical products and medical devices. Mr. Schleifer received his BA in Psychology from Kenyon College and holds an MBA from Babson College.

Lisa Mastromattei has over 25 years of experience in Finance & Accounting, primarily in the medical device industry.  Prior to joining Mitralign, Lisa held several leadership roles including Director of Accounting at Orchard Brands, a direct marketing/ecommerce business.  Global Controller at Microline Surgical, a manufacturer of high precision laparoscopic instruments.  Lisa also spent 15 years at Abbott Laboratories, Diabetes Care division.  She received her bachelor’s degree cum laude from Suffolk University in Finance and holds a Six Sigma Black Belt.

Mr. Oppenheim brings 20 years of diverse operations experience serving medical, defense, scientific, industrial, and automotive markets.  In addition to operations, he has held strategic roles in product management and business integration.  Mr. Oppenheim received his BS from the University of Great Falls, an MBA from the University of Massachusetts Lowell, and is a Certified Six Sigma Blackbelt.

Mr. Lee has over 20 years of experience in development and manufacturing of medical devices. Prior to joining Mitralign, he was with LightLab Imaging, now part of St. Jude Medical, Inc. Mr. Lee has held product development leadership roles at Surgivision, GMP Companies, C.R. Bard, Inc./AVE and Medtronic. He has a BS cum laude in Mechanical Engineering from Northeastern University.

Sara Vidmar has over 20 years of medical device experience with a focus on cardiovascular products and procedures. Prior to joining Mitralign, Sara held several roles at Medtronic including leading the clinical organizations for the Structural Heart and Cardiac Rhythm Heart Failure Management as well as a corporate clinical leadership role focused on addressing the need for real-world, longitudinal product performance and patient safety data. Sara’s other prior roles included Vice President, Clinical Research and Scientific Affairs at Lutonix-CR Bard where she was responsible for achieving FDA and global regulatory approvals for the drug-coated balloon therapy. Sara received her bachelor’s degree from University of Colorado, Boulder in Molecular, Cellular, Developmental Biology and her MBA from University of St. Thomas in Healthcare Management.

Mr. Geoffrion currently serves as the President and Chief Executive Officer of Mitralign, a venture-backed private company that has developed a transcatheter platform for mitral and tricuspid valve repair. Rick has over 30 years of management experience in the medical device industry and more than 25 years in the cardiovascular device space. A co-founder of Mitralign, he previously led the company foundation and served as the early stage CEO for three additional medical device companies (CircuLite, FlowMedica, X-Cell). He also guided the recapitalization and redirection of two successful medical device companies (Impella, Pathway). Mr. Geoffrion served as the Chairman of Impella CardioSystems AG, CircuLite and FlowMedica, Inc. He holds a BSME and an MBA from the University of Connecticut.

Ms. Bates is managing partner of Triathlon Medical Ventures. She has over 20 years of venture and operating experience, with a focus on medical devices and pharmaceuticals. At Guidant Corp., she ran Compass, its ventures group. Prior to that, she held various senior management operating positions at Eli Lilly. She is Chairman of the Board of CS-Keys, Inc. and on the Board of Directors at Pradama. She was also on the Board of Directors at Remon Medical Technologies before its acquisition of Boston Scientific. Ms. Bates has an MBA from Stanford, a BS in Finance and a BS in Computer Science; she is also a CPA.

Dr. Binur is a managing partner of Orchestra and has over 29 years of venture capital experience in the United States, Europe and Israel. He is co-founder of Accelerated Technologies, Inc. and served as its Chairman of the Board since its inception. He was founding Managing Partner of Medica and while there helped raise its first two venture funds. In addition, he led the deployment of $140 million in investments into early stage healthcare technology companies. Dr. Binur also co-founded and led the financing for PVT, an ATI Portfolio company. He is a director of Mitralign, Vital Access and SuperDimension, Ltd., a pioneer of interventional pulmonology. He holds a BS in electrical engineering from the Technion Institute in Israel and PhD in physics from MIT/Tel Aviv University.

Mr. Cole is a venture partner in Oxford Bioscience Partners and general partner of Spray Venture Partners. He has 20 years of medical device operational experience and has served on boards of 16 med-tech companies. He was SVP and Group President of Boston Scientific’s vascular business, a $1.2 billion group (including SCIMED, Medi-tech, Meadox and EP Technologies. Mr. Cole was previously President and COO of SCIMED Life Systems, prior to merging with Boston Scientific. He’s also held a variety of executive and general management positions at Baxter Healthcare Divisions. He currently serves on the Boards of IntraPace, Pathway Medical, Tryton Medical, Direct Flow Medical and Thoratec Laboratories.

Aditya Puri is an Investment Partner at Xeraya Capital, which is responsible for life sciences investments for Khazanah Nasional Berhad, the Malaysian government’s strategic investment fund.  He joined Khazanah Nasional’s Life Sciences team after moving from the greater Boston area where he was working with Healthcare and Cleantech startups affiliated with Harvard and MIT.  He has more than 20 years of experience and leadership encompassing general management, private equity and venture investments, and international expansion across life science and technology industries.  His prior experience includes P&L responsibility and leadership positions at Yankee Group, a global technology research and consulting company, and Corporate Development at Boston Scientific, a Fortune 500 medical device manufacturer.  He serves on boards of multiple public and private life sciences companies in the US, and private companies outside the US.  He received his B.S. from the University of Southern Maine, graduating Summa Cum Laude, and his MBA from the MIT Sloan School of Management. He has also passed all parts of the U.S. Uniform CPA Examination.

Mr. Van Osch was a founding partner of Forbion Capital Partners. He currently serves on the Board of Directors for CircuLite, PneumRx and Santaris Pharma AS. Mr. Van Osch’s experience in the life sciences industry also includes positions at Cambridge Drug Discovery Ltd, Impella Cardiosystems, Acadia Pharmaceuticals and Flowmedica. While at ABN AMRO Capital, he developed the Medical Device investment strategy by joining the ATI incubator initiative which focused on start-ups in interventional cardiology.

Please indicate your site location

Mitralign, Inc.

This site may contain information on worldwide products, not all of which are available in every location. A reference to a product on this site does not imply that such product is or will be available in your location. The products referred to on this site may be subject to different regulatory requirements depending on the country of use. Consequently, visitors may be notified that certain sections of this site are intended only for health care professionals in certain countries. For the availability of a particular product in your country, please contact the company directly.